Organogenesis Holdings Inc. Updates Date and Time of Presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

CANTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the date and time of its presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit has been updated.

Continue reading here:
Organogenesis Holdings Inc. Updates Date and Time of Presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Axiom Presenting “Data Driven Studies: Unified eClinical Platforms to Run Your Clinical Trials” at The Virtual MedTech Conference 2020

Go here to read the rest:
Axiom Presenting “Data Driven Studies: Unified eClinical Platforms to Run Your Clinical Trials” at The Virtual MedTech Conference 2020

Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020

-  AUTO3 shows promise of a highly differentiated product profile

Read the original here:
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020

COMPASS Pathways announces pricing of upsized initial public offering

Follow this link:
COMPASS Pathways announces pricing of upsized initial public offering

Immutep Reports Improving Results from INSIGHT-004 Trial

SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial. The data were presented at the ESMO Virtual Congress 2020 on 17 September 2020, CEST (poster ID number 1032P) by trial investigator at Institute of Clinical Cancer Research, Krankenhaus Nordwest (IKF), PD Dr. Thorsten Götze.

Follow this link:
Immutep Reports Improving Results from INSIGHT-004 Trial

Enosi Life Sciences Appoints Biotech, Pharma and Venture Capital Veteran Dr. James N. Woody as Executive Chairman

Dr. James Woody’s leadership qualities and experience leading innovative pharmaceutical ventures and raising funds will power Enosi’s development of second-generation anti-TNF therapeutics for inflammatory autoimmune diseases and cancer.

Read more:
Enosi Life Sciences Appoints Biotech, Pharma and Venture Capital Veteran Dr. James N. Woody as Executive Chairman

Motus GI Expands Intellectual Property Portfolio with Chinese Patent for its Method to Mount the Pure-Vu® System on the End of a Colonoscope

FORT LAUDERDALE, Fla., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that the China National Intellectual Property Administration ("CNIPA") issued patent 201680002365, titled “Distal Front End for Coordination Positioning of an Endoscope with a Suction Device.” The patent covers the method of mounting Motus GI’s proprietary sensing technology and enhanced suction systems with the distal end of a colonoscope. This patent further protects the Company’s flagship product – the Pure-Vu® System – in this key potential market.

Continue reading here:
Motus GI Expands Intellectual Property Portfolio with Chinese Patent for its Method to Mount the Pure-Vu® System on the End of a Colonoscope

Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in two poster presentations at the ESMO Virtual Congress 2020 on 17 September 2020 and relates to the cut-off date of 21 August 2020.

See the original post here:
Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

CORRECTING and REPLACING – Zogenix Appoints Three Industry Leaders to Its Board of Directors

Correction: In this updated news release issued September 21, 2020 by Zogenix, Inc, the name of the organization, WorldWideWomen, has been corrected. The full corrected press release follows.

Read more here:
CORRECTING and REPLACING - Zogenix Appoints Three Industry Leaders to Its Board of Directors

Valneva Announces Retirement of Chief Financial Officer David Lawrence

Saint-Herblain (France), September 18, 2020 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced the retirement of its Chief Financial Officer, David Lawrence, at the end of 2020.

More:
Valneva Announces Retirement of Chief Financial Officer David Lawrence